Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

Two other cybersecurity researchers, who were not authorized to speak publicly about their analysis, confirmed that the web domains and hosting servers used in the hacking attempts were linked to Iran.

An experimental antiviral drug developed by a research-based biopharmaceutical company, Gilead Sciences showed positive results on its application, where more than half of a group of severely ill coronavirus patients improved. UPDATE: On 29 April, Gilead Sciences Inc. announced that in Phase

In one case, A fake email login page designed to steal passwords was sent in April to a top Gilead executive involved in legal and corporate affairs, according to an archived version on a website used to scan for malicious web addresses. Reuters was not able to determine whether the attack was successful.

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy a treatment for the COVID-19 virus.

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy a treatment for the COVID-19 virus.

Recent clinical trial results and the decision by the US Food and Drug Administration to issue 'Emergency Use Authorisation' for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally, Gilead said.

All of that could add up to market wins if remdesivir lives up to expectations and Gilead can ramp up to sufficiently respond to Covid-driven demand. But if it can’t, Gilead could be “very vulnerable” to the federal government using its powers to compel the licensure of remdesivir patents, Roth said.

Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.

Checks with industry on when can production begin here for trials

Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine

The $4.9 billion deal adds a mid-stage cancer drug to the big biotech's pipeline

Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine

Gilead toma ventaja gracias a un antiviral, mientras que Moderna está buscando una nueva vacuna ARNm.

Limited results from a NIAID study suggest the drug helps people with COVID-19 recover faster

Gilead said it was in discussions with 'some of the world’s leading chemical and pharmaceutical manufacturing companies' to produce remdesivir for Europe, Asia and the developing world through at least 2022